Join a pioneering conference focused on the development of human-relevant in vitro disease models. The program brings together leading biologists, bioengineers, clinical researchers, computational researchers and industry experts to explore two key areas: in vitro engineering of human tissues and tissue-cell interaction modelling. It will address critical challenges in disease model manufacturing, characterization methods, and benchmarking protocols.
Sessions will examine how these in vitro disease models can support drug development, pre-clinical testing and inclusive biomedical research. This conference offers valuable insights for professionals across biotechnology, pharmaceutical development, and clinical research sectors, providing a platform to engage with cutting-edge innovations in disease modeling and therapeutic discovery.
Serving as a companion event, you are also invited to join the fourth version of The AI 4 Life: Biotech Future Forum on October 27th. Centered on artificial intelligence and biotechnology, this forum explores the transformative impact of these fields on future developments and scientific advancements. Led by Serbia's Government and its Centre for the Fourth Industrial Revolution, in partnership with the World Economic Forum and UNDP, it brings together diverse stakeholders from governmental bodies, industrial sectors, academic institutions, and international participants
Event details
Speakers
Natalia Trayanova
Professor of Biomedical Engineering
Johns Hopkins University
Milica Radisic
Professor
University of Toronto
Margherita Turco
Group Leader
Turco Friedrich Miescher Institute for Biomedical Research
Gordana Vunjak-Novakovic
Professor
Columbia University
Sarah Hedtrich
Associate Professor
School of Biomedical Engineering, University of British Columbia
Seung-Woo Cho
Professor
Yonsei University
Christopher J Stewart
Chair of Human Microbiome Research
Newcastle University
Ankur Singh
Professor
Georgia Institute of Technology
Jürgen Knoblich
Scientific Director
Austrian Academy of Science
Matthias Lütolf
Professor
IHB, Roche and EPFL
Professor Matthias Lutolf is the founding director of Roche’s Institute of Human Biology (IHB) where he leads the Translational Bioengineering department. The IHB focuses on pioneering research in organoids, human biology, and translational bioengineering, bridging the gap between academic and pharmaceutical research. Lutolf's academic journey began at ETH Zurich, where he studied materials engineering and earned a PhD in biomedical engineering. Following his postdoctoral studies at Stanford University, he established his own laboratory at EPFL in 2007. From 2014 to 2018, he served as the director of EPFL’s Institute of Bioengineering. Lutolf’s own research at IHB is dedicated to developing advanced bioengineering strategies to create next-generation organoids with enhanced reproducibility and physiological relevance, essential for early drug development. His teams' work has been published in renowned journals such as Nature and Science. Additionally, his innovations have led to the commercialization of products, including devices and assays for personalized medicine, and the co-founding of biotech startups in Lausanne.
Hans Clevers
Head of pharma Research and Early Development
Hubrecht Institute for Developmental Biology and Stem Cell Research (KNAW)
Sarah Christine Heilshorn
Professor
Stanford University
Early Bird rates are available for a limited time
SAVE $50
REGISTER TODAY!
SAVE $50
REGISTER TODAY!